Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Implications of Oral Oncolytics
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.
